Carillon Tower Advisers Inc. Has $20.47 Million Stake in Pfizer Inc. (PFE)

Carillon Tower Advisers Inc. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 564,091 shares of the biopharmaceutical company’s stock after selling 9,665 shares during the quarter. Carillon Tower Advisers Inc.’s holdings in Pfizer were worth $20,465,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Naples Global Advisors LLC grew its holdings in Pfizer by 5.4% during the second quarter. Naples Global Advisors LLC now owns 33,695 shares of the biopharmaceutical company’s stock valued at $1,222,000 after purchasing an additional 1,712 shares during the period. Steward Partners Investment Advisory LLC grew its holdings in Pfizer by 25.1% during the second quarter. Steward Partners Investment Advisory LLC now owns 285,325 shares of the biopharmaceutical company’s stock valued at $10,352,000 after purchasing an additional 57,176 shares during the period. Destination Wealth Management grew its holdings in Pfizer by 962,667.3% during the second quarter. Destination Wealth Management now owns 500,639 shares of the biopharmaceutical company’s stock valued at $18,163,000 after purchasing an additional 500,587 shares during the period. Gagnon Securities LLC grew its holdings in Pfizer by 61.1% during the first quarter. Gagnon Securities LLC now owns 14,708 shares of the biopharmaceutical company’s stock valued at $522,000 after purchasing an additional 5,581 shares during the period. Finally, Pennsylvania Trust Co grew its holdings in Pfizer by 10.9% during the second quarter. Pennsylvania Trust Co now owns 681,255 shares of the biopharmaceutical company’s stock valued at $28,127,000 after purchasing an additional 67,151 shares during the period. Institutional investors own 68.96% of the company’s stock.

Shares of PFE opened at $44.28 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.91 and a current ratio of 1.16. Pfizer Inc. has a twelve month low of $33.20 and a twelve month high of $45.81. The company has a market capitalization of $256.03 billion, a price-to-earnings ratio of 16.71, a P/E/G ratio of 2.17 and a beta of 0.88.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.03. Pfizer had a net margin of 44.63% and a return on equity of 25.34%. The firm had revenue of $13.30 billion for the quarter, compared to analyst estimates of $13.53 billion. During the same quarter in the previous year, the firm posted $0.67 earnings per share. The business’s revenue was up 1.0% on a year-over-year basis. Analysts anticipate that Pfizer Inc. will post 3 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Friday, November 9th will be paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 3.07%. The ex-dividend date is Thursday, November 8th. Pfizer’s payout ratio is currently 51.32%.

In other Pfizer news, insider Laurie J. Olson sold 10,214 shares of Pfizer stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $41.00, for a total value of $418,774.00. Following the transaction, the insider now owns 72,672 shares of the company’s stock, valued at $2,979,552. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Pfizer Inc purchased 55,556 shares of the business’s stock in a transaction on Monday, October 15th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $1,000,008.00. Following the purchase, the insider now owns 21,976,484 shares of the company’s stock, valued at approximately $395,576,712. The disclosure for this purchase can be found here. Insiders own 0.06% of the company’s stock.

A number of research analysts recently issued reports on PFE shares. JPMorgan Chase & Co. restated a “$37.66” rating on shares of Pfizer in a report on Wednesday, July 18th. Cantor Fitzgerald set a $45.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, July 31st. BMO Capital Markets restated a “buy” rating and set a $42.00 price objective on shares of Pfizer in a report on Thursday, July 19th. Bank of America boosted their price objective on shares of Pfizer from $42.00 to $43.00 and gave the company a “buy” rating in a report on Wednesday, August 1st. Finally, Morningstar set a $45.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, August 8th. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $42.67.

ILLEGAL ACTIVITY NOTICE: “Carillon Tower Advisers Inc. Has $20.47 Million Stake in Pfizer Inc. (PFE)” was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/11/10/carillon-tower-advisers-inc-has-20-47-million-stake-in-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Recommended Story: What are earnings reports?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply